BioPharmSignal logoBioPharmSignal

Biotech News

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Company update

SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that

Related news

OLMAOlema Pharmaceuticals, Inc.2026-08-04 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KURAKura Oncology2026-08-07 11:30 EST

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

IMTXImmatics2026-07-17 14:25 EST

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

FATEFate Therapeutics2026-06-01 12:30 EST

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

View all latest news

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

OLMAOlema Pharmaceuticals, Inc.2026-08-04 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-07-02 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-06-02 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-05-26 11:00 EST

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer

OLMAOlema Pharmaceuticals, Inc.2026-05-21 21:00 EST

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Stock data

Close
11.80 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States